Page contentsPage contents Key facts Decision Key facts Active substance rinatabart sesutecan Therapeutic area Investigations Decision number EMA/PE/0000230375 PIP number EMA/PE/0000230375 Pharmaceutical form(s) All pharmaceutical forms Condition(s) / indication(s) Treatment of peritoneal cancer Route(s) of administration All routes of administration Contact for public enquiries Genmab A/S Tel.: +45 70202728E-mail: clinicaltrials@genmab.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 28/01/2025 Compliance check done No Decision EMA/PE/0000230375 : EMA decision of 28 January 2025 on the granting of a product specific waiver for rinatabart sesutecanAdopted Reference Number: EMADOC-1700519818-1840321 English (EN) (190.45 KB - PDF)First published: 10/03/2026 View Share this page